Skip to main content
. Author manuscript; available in PMC: 2011 Dec 15.
Published in final edited form as: Clin Cancer Res. 2010 Dec 15;16(24):6029–6039. doi: 10.1158/1078-0432.CCR-10-1490

Figure 3.

Figure 3

Panels A: ANOVA analysis of IC50s of the dual PI3K/mTOR inhibitor NVP-BEZ-235 in 23 melanoma cell lines showing no significant difference in sensitivity to this compound in B-Raf mutant and B-Raf wild type cells. Panel B: Decreases in pAkt and pP70S6K in a dose- and time-dependant fashion in two melanoma cell lines treated with NVP-BEZ-235. pP70S6K levels are undetectable at all concentrations and time points studied, whereas levels of pAkt start rising again after 4 hours of drug exposure in a dose-dependant fashion. Panels C: Clonogenic assays in two melanoma cell lines (YUVON and YUSIK) treated with NVP-BEZ-235 at different concentrations. NVP-BEZ235 was effective in inhibiting colony formation at low nanomolar concentrations.